Medicenna Therapeutics Corp. (MDNAF.PK), Thursday announced the appointment of Dr. Nageatte Ibrahim as Chief Medical Officer of the company.
Previously, Dr. Ibrahim served as Chief Medical Officer of Oncology at Innovent Biologics USA, where she established and led a global clinical development organization and played a key role in building the company's U.S. presence.
Commenting on the appointment, Dr. Ibrahim said, "The company's IL-2 superagonist programs, MDNA11 and MDNA113, hold promise to improve outcomes for patients with various solid tumors with bizaxofusp (MDNA55) demonstrating compelling evidence of efficacy in patients with glioblastoma, one of the most challenging cancers with significant unmet needs. I look forward to working with the team to accelerate the clinical development of these therapies."
MDNAF closed trading at $0.46, up 4.31 percent on the OTC Markets.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.